Article Text

Download PDFPDF

Clinical and research medicine: Hypertension
e0590 The one-year pharmacoeconomic evaluation of hypertension′s treatment by low dose amlodipine plus telmisartan or amlodipine plus amiroride regimen
  1. Haiqiang Sang1,
  2. Ming Sun2,
  3. Hongyan Zhou2
  1. 1Zhengzhou People's Hospital
  2. 2Xiangya Hospital of Central South University


Objective To evaluate the cost-effectiveness of low-dose amlodipine plus telmisartan (group A) or amlodipine plus amiroride (group B) therapy in hypertensive patients using a decision-tree model with a time horizon of 1 year. To provide evidence on the optimal combination therapy regimens and treatment options in hypertensive patients.

Method Based on the trial data, a cost-effectiveness decision-tree model was developed to assess, about 1 year period, the short-time economic effects, where the total effective rates, Blood pressure control rates and QALYs were estimated as indicators of effectiveness, respectively. Roll back, cost-effectiveness analysis, cost-utility analysis and incremental cost-effectiveness analysis wore adopted in the decision-tree model. Both one-way and two-way sensitivity analysis were carried out to determine the robustness of our baseline results.

Results 1. Expected values: About the average cost per patient needed with a time horizon of 1 year, group A need ¥1247, group B need ¥1917. About the total effective rates and blood pressure control rates, group A reached 87.6% and 80.9%, group B reached 84.0% and 70.7%. About the average QALYs per patient gained, group A were 0.046 QALYs and group B were 0.085 QALYs. 2. The one year cost-effectiveness analysis showed that, the cost of effective treatment was ¥1389 and ¥2230 per patient in group A and group B, respectively.At the cost of blood pressure controlled for each case, group A need ¥1540, and group B require ¥2712. At the cost of gain 1 QALY after 1 year therapy, group A need ¥26979, and group B require ¥22517. The estimated ICER for group A vs group B was ¥17222 per QALY gained. 3. The sensitivity analysis results showed that there were no impact of variations in key model inputs on the model.

Conclusion From group decision-making considerations, applying the economic benefit, the initial low-dose amlodipine plus amiloride is optimal opinion; And consider from improving the quality of life, amlodipine plus telmisartan is prefered scheme.

  • Hypertension
  • combination therapy
  • decision-tree model
  • cost-effectiveness analysis
  • cost-utility analysis
  • incremental analysis
  • pharmacoeconomics evaluation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.